NEW YORK — Quest Diagnostics said Thursday that its Haystack Oncology subsidiary has entered a collaboration agreement with Rutgers Cancer Institute of New Jersey for a study of early-stage triple-negative breast cancer patients.
Researchers will use Haystack's MRD technology to help evaluate therapeutic response and collect molecular information on individuals undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin.
Financial and other terms of the agreement were not disclosed.
"Triple-negative breast cancer is a subtype of breast cancer that is aggressive by nature with a complex biology; therefore, the disease tends to have a worse prognosis," Mridula George, associate program director of Breast Medical Oncology at Rutgers Cancer Institute and principal investigator of the study, said in a statement. "We are excited to use Haystack's MRD technology to monitor treatment response in our clinical trial that could help inform future studies and novel approaches that will result in better outcomes for our patients."
"We're excited to work with Rutgers Cancer Institute in their efforts to optimize therapeutic strategies for patients with early-stage breast cancer," Dan Edelstein, VP and general manager of Haystack Oncology, said in the statement. "With unparalleled sensitivity, Haystack MRD provides a tool for anticipating and evaluating treatment-related benefits to a greater depth than standard clinical and radiographic metrics, making it well equipped to support clinical studies such as this, which are essential for advancing cancer care."